The previous articles in this supplement have outlined the role of the lung cancer nurse specialist in delivering high quality care for patients with advanced ALK-positive non-small cell lung cancer from investigations and diagnosis through to treatment and toxicity management. This third, and final, article suggests ways of maximising adherence to ceritinib so that patients can achieve the best possible treatment outcome